Internal Medicine · Houston, TX
NPI
1730245911
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1515 Holcombe Blvd
Houston, TX, 77030
Phone (713) 792-6161
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
184 services
Medicare patients, 2024
78
Average age 74
Drug cost, 2024
$1.5M
154 prescriptions
Company payments, 2025
$22K
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lauren A Byers was code 99215 (office e&m - established), 101 times for 46 patients. In total Lauren A Byers billed 184 services in 11 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-07-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 101 | 46 | $109.45 | $11K |
| 99214 Office E&M - Established | Facility | 34 | 25 | $76.03 | $2,585 |
| 99205 Office E&M - New | Facility | 17 | 17 | $145.29 | $2,470 |
By year: 2022 $18K for 198 services; 2023 $25K for 264 services; 2024 $18K for 184 services.
Medicare prescription drug claims, 2024
In 2024, the drug Lauren A Byers prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 45 prescriptions and refills. In total Lauren A Byers wrote 154 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 45 | 45 | Under 11 | $740K |
| Gilotrif Afatinib Dimaleate | 15 | 15 | Under 11 | $173K |
| Gavreto Pralsetinib | 13 | 13 | Under 11 | $290K |
| Ondansetron Hcl Generic | 11 | 11 | Under 11 | $88.43 |
Brand drugs: 86 claims; generic drugs: 68 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lauren A Byers $22K ($22K in general payments such as food, travel and fees and $93 for research) from 10 companies. The largest payer was AstraZeneca UK Limited with $7,790.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca UK Limited AZN | 5 | $7,790 |
| Gilead Sciences, Inc. GILD | 4 | $4,744 |
| Genentech USA, Inc. ROG.SW | 4 | $3,429 |
| Amgen Inc. AMGN | 2 | $2,842 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $2,185 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $675 |
| Abbvie Inc. ABBV | 2 | $138 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $35.1 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $13.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.